Patents Assigned to United Therapeutics Corporation
  • TREPROSTINIL PRODUCTION
    Publication number: 20150105582
    Abstract: The present invention is directed to a novel method for preparing a synthetic intermediates for treprostinil. Also described are methods of preparing treprostinil comprising utilizing novel intermediates described herein as well as novel intermediates useful for synthesis prostacyclin derivatives, such as treprostinil.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh
  • Treatment for pulmonary hypertension
    Patent number: 8969409
    Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: March 3, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Martine A. Rothblatt, Lewis J. Rubin
  • Treprostinil production
    Patent number: 8940930
    Abstract: The present invention is directed to a novel method for preparing a synthetic intermediates for treprostinil. Also described are methods of preparing treprostinil comprising utilizing novel intermediates described herein as well as novel intermediates useful for synthesis prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: January 27, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Raju Penmasta, Vijay Sharma, Sudersan M. Tuladhar, David A. Walsh
  • COMPOUNDS AND METHODS FOR DELIVERY OF PROSTACYCLIN ANALOGS
    Publication number: 20150005374
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Application
    Filed: September 18, 2014
    Publication date: January 1, 2015
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, David MOTTOLA, Roger Jeffs
  • CONTROLLED RELEASE PHARMACEUTICAL FORMULATIONS
    Publication number: 20140323567
    Abstract: Disclosed herein are drug release polymer compounds and compositions comprising prostacyclin compounds of Formula (I), and methods of preparing the same.
    Type: Application
    Filed: April 29, 2014
    Publication date: October 30, 2014
    Applicant: United Therapeutics Corporation
    Inventor: Peter Laing
  • PROCESS OF MAKING PROSTACYCLIN COMPOUNDS WITH LINKER THIOL AND PEGYLATED FORMS
    Publication number: 20140288314
    Abstract: A process provides for producing chiral prostacyclin derivatives of Formula (I) in high yield from meso anhydrides.
    Type: Application
    Filed: March 24, 2014
    Publication date: September 25, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Liang Guo
  • SOLID FORMS OF TREPROSTINIL
    Publication number: 20140275262
    Abstract: There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Ken Phares, Michael Scannell
  • SALTS OF TREPROSTINIL
    Publication number: 20140275616
    Abstract: Provided are novel treprostinil salts as well as methods for making treprostinil salts.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Hitesh Batra, Vijay Sharma, Sanmin Yang, Yi Zhang
  • TREATMENT OF VASCULOPATHY WITH PROSTACYCLIN AND MESENCHYMAL STEM CELLS
    Publication number: 20140193379
    Abstract: Provided are methods for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 10, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Roger Jeffs, Thomas Petersen, Roger M. Ilagan, Michael Wade
  • BUFFER SOLUTIONS HAVING SELECTIVE BACTERICIDAL ACTIVITY AGAINST GRAM NEGATIVE BACTERIA AND METHODS OF USING SAME
    Publication number: 20140194520
    Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
    Type: Application
    Filed: January 17, 2014
    Publication date: July 10, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Roger Andrew Jeffs, David Zaccardelli
  • Use of treprostinil to treat and prevent ischemic lesions
    Patent number: 8765813
    Abstract: The present disclosure relates to novel methods for using treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The disclosure also relates to kits for treatment and/or prevention of ischemic lesions, which include an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: July 1, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Michael Wade, Roger Jeffs, Robert Roscigno, Deborah Strootman, Kathryn Bronstein
  • Process to prepare treprostinil
    Patent number: 8748657
    Abstract: This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: June 10, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, Raju Penmasta, David A. Walsh
  • Iminosugars and methods of treating togaviral diseases
    Patent number: 8748460
    Abstract: Provided are novel methods of treating and/or preventing a disease or condition caused by or associated with a virus belonging to the Togaviridae family using iminosugars, such as DNJ derivatives.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: June 10, 2014
    Assignees: United Therapeutics Corporation, The Chancellor, Masters and Scholars of the University of Oxford
    Inventors: Urban Ramstedt, Brennan Klose, Nicole Zitzmann, Raymond A. Dwek, Terry D. Butters
  • Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
    Patent number: 8658694
    Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: February 25, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Roger Andrew Jeffs, David Zaccardelli
  • Nebulized liposomes for the pulmonary application of drug compounds
    Patent number: 8652512
    Abstract: The present invention discloses a method to prepare specific liposomal formulations for the pulmonary application of therapeutic substances. The liposomal components, DPPC and cholesterol at a molar ratio of 7:3 and 7:4, respectively, are combined with the non-toxic excipients, sphingomyelin, dimyristoylphophatidylcholine and/or polyethylene glycol, to prepare liposomes that are stabile during nebulization with commercially available nebulizers and exhibit sustained release kinetics of encapsulated drug substances.
    Type: Grant
    Filed: April 4, 2003
    Date of Patent: February 18, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Thomas Schmehl, Tobias Gessler, Esther Waschkowitz
  • Buffer solutions having selective bactericidal activity against gram negative bacteria and methods of using same
    Patent number: 8653137
    Abstract: Buffer solutions for pharmaceutical preparations that have bactericidal activity preferentially against gram negative bacteria are provided. The buffers have a pH of greater than about 10 or less than about 4.5 with low buffer capacity. Methods of their use in reducing the occurrence of blood stream infections in a mammal is also provided.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 18, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Roger Andrew Jeffs, David Zaccardelli
  • TREPROSTINIL TREATMENT FOR INTERSTITIAL LUNG DISEASE AND ASTHMA
    Publication number: 20140018431
    Abstract: The present invention describes methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of interstitial lung disease or asthma, or a condition, such as pulmonary fibrosis, associated with interstitial lung disease or a condition associated with asthma. The invention also relates to kits for treatment and/or prevention of such condition that include an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2013
    Publication date: January 16, 2014
    Applicant: United Therapeutics Corporation
    Inventors: Michael Wade, Stuart Rich, Eugene Sullivan, Robert Roscigno, Roger Jeffs
  • Treatment for pulmonary hypertension
    Patent number: 8609728
    Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.
    Type: Grant
    Filed: March 14, 2011
    Date of Patent: December 17, 2013
    Assignee: United Therapeutics Corporation
    Inventors: Martine A. Rothblatt, Lewis J. Rubin
  • Use of treprostinil to treat neuropathic diabetic foot ulcers
    Patent number: 8563614
    Abstract: The present invention describes novel methods for using 9-deoxy-2?,9-?-methano-3-oxa-4,5,6-trinor-3,7-(1?,3?-interphenylene)-13,14-dihydro-prostaglandin F1 (also known as Treprostinil) or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of foot ulcers in subjects with diabetic neuropathy. The invention also relates to kits for treatment and/or prevention of foot ulcers, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: October 22, 2013
    Assignee: United Therapeutics Corporation
    Inventors: Michael Wade, Roger Andrew Jeffs, Deborah Strootman
  • TREATMENT FOR PULMONARY HYPERTENSION
    Publication number: 20130253049
    Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.
    Type: Application
    Filed: May 22, 2013
    Publication date: September 26, 2013
    Applicant: United Therapeutics Corporation
    Inventors: Martine A. Rothblatt, Lewis J. Rubin